Lazarus Rochelle B - Jun 10, 2022 Form 4 Insider Report for Organon & Co. (OGN)

Role: Director
Signature: /s/ Tarnetta V. Jones, as Attorney-in-Fact for Rochelle B. Lazarus
Stock symbol: OGN
Transactions as of: Jun 10, 2022
Transactions value $: $199,994
Form type: 4
Date filed: 6/14/2022, 07:34 PM
Previous filing: Jul 13, 2021
Next filing: Jul 11, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	OGN	Common Stock						458	Jun 10, 2022	Direct	F1
holding	OGN	Common Stock						175	Jun 10, 2022	By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OGN	Phantom Stock	Award	$200K	+5.64K	+62.68%	$35.46	14.6K	Jun 10, 2022	Common Stock	5.64K		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The number of shares of Organon & Co. ("Organon") common stock previously reported has been adjusted based on the finalization of certain calculations in connection with the separation of Organon from Merck & Co., Inc.
F2	Each phantom stock unit is an economic equivalent of one share of Organon common stock, or 1-for-1.
F3	Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.
F4	Holdings include phantom stock acquired in dividend reinvestment transactions on September 13, 2021, December 16, 2021 and March 17, 2022.